SafeHeal(R) Closes Oversubscribed €35 Million Series C Equity Financing
Press Releases SafeHeal(R) Closes Oversubscribed €35 Million Series C Equity Financing
Financing led by Solar Eclipse with new investors Gideon Strategic Partners and M&L Healthcare, part of M&L Group, and returning investors Sofinnova Partners and one of the largest Multinational life sciences corporations from a strategic standpoint.
Proceeds will support the completion of SafeHeal's IDE pivotal study and preparation for commercial launch of their lead technology, Colovac®.
SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced a successful completion of an oversubscribed €35 million Series C equity financing to validate the use of Colovac®, a groundbreaking temporary endoluminal fecal bypass system. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection.
The proceeds leave SafeHeal well-funded to complete its IDE Pivotal study and accelerate preparation for commercial launch of their lead technology, Colovac.
In conjunction with the financing, Martin Sands and Steven Sands of Solar Eclipse will join as board member and observer respectively.
The Colovac endoluminal bypass system is a less-invasive alternative to temporary diverting ostomy, the current standard of care for patients undergoing colorectal resection. Diverting ostomy is applied prophylactically to most patients today undergoing a low anterior resection (LAR) and anastomosis. The ostomy temporarily diverts the stool away from the healing anastomosis to the outside of the body and into an ostomy bag. In most cases, the ostomy is needed only until the anastomosis has healed, and then it can be reversed, typically after 2-6 months. The eventual reversal of the ostomy requires another operation, with a second hospital stay, recovery period and associated complications. In some cases, the ostomy may not be reversed and becomes permanent. In addition to the potential surgical complications associated with ostomy procedures, patients may experience an impact to their quality of life due to social isolation, reduced physical activity and/or intimacy.
Colovac is an alternative to diverting ostomy, designed to eliminate the need for a temporary stoma in most patients. It aims to improve patient recovery and quality of life by eliminating stoma related complications including permanent stoma and eliminating the physical and emotional burden associated with stoma management and care.
Colovac has been successfully studied in over 100 patients in the U.S., Europe, and Asia and has received FDA Breakthrough Designation status.
"This is a very exciting time at SafeHeal as we continue to achieve a number of critical value-creating milestones in the coming months," said Chris Richardson, President and Chief Executive Officer. "We are grateful for the continuing support from Sofinnova Partners and delighted to welcome Solar Eclipse, Gideon and M&L Healthcare, part of M&L Group as new investors. This capital raise places SafeHeal in an excellent position to continue our momentum toward FDA approval and commercialization of Colovac."
Chris Richardson, President & CEO, SafeHeal
"The current standard of care for treatment of Colon Resection is associated with significant morbidity, risk of permanent stoma and reduced quality of life, driving both the clinical community and regulators to search for better treatment options. SafeHeal is addressing this significant unmet medical need with a highly novel approach," said Martin Sands of Solar Eclipse. "I believe SafeHeal's therapeutic platform will dramatically improve quality of life and outcomes for patients with Colon Resections. I look forward to supporting the team to achieve multiple key milestones over the next 18 months."
"We've been with SafeHeal since day one, when it was born out of our Medtech accelerator, MDStart. Our continued support in this Series C reflects a deep growing belief in their potential to revolutionize care for patients facing ostomy," said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners.
ABOUT SAFEHEAL®
SafeHeal SAS, headquartered in Paris, France, and its wholly owned U.S. subsidiary, SafeHeal Inc., is a clinical-stage medical device company developing Colovac, a device intended as an alternative to diverting ostomy in patients undergoing colorectal surgery. Colovac is a flexible endoluminal bypass sheath designed to reduce the contact of fecal content at the anastomotic site following colorectal surgery. The device is placed endoluminally and is fully reversible. The device remains in place for 7-10 days, until the body's natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. This enables patients to resume their normal life without the stigma and complications associated with an ostomy procedure. Colovac is an investigational device, not currently available for sale. For more information, please visit www.safeheal.com
MEDIA CONTACTS
USA
Scott DePierro
Vice President U.S. Operations
and Global Business Development, SafeHeal
203-444-0279
sdepierro@safeheal.com
www.safeheal.com
Europe:
Karl-Heinz Blohm
Vice President, International, SafeHeal
+33 (0) 6 5181 7895
kblohm@safeheal.com
www.safeheal.com
###
SOURCE: SafeHeal
This story was originally published May 6, 2025 at 8:06 AM.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
USA Today
4 hours ago
- USA Today
Wildfire smoke, shark pardons and lost 401(k) accounts: Your week in review
Wildfire smoke, shark pardons and lost 401(k) accounts: Your week in review Show Caption Hide Caption Smoke drifting into US from Canada wildfires could impact health Smoke from wildfires in Canada has drifted into Montana, the Dakotas, Minnesota, Midwestern and East Coast states, and as far south as Florida. Canadian wildfire smoke hangs over U.S. Skies were looking milky across much of the United States for days as smoke from wildfires raging in Canada drifted into northern and Midwestern states and dipped even as far south as Florida. The Dakotas, Iowa and most of Minnesota and Wisconsin were under air quality alerts, and the haze hung over major cities including New York, Washington, Philadelphia and Boston. More than 200 wildfires were burning in Canada as of June 3, and more than half were classified as "out of control," Canadian forest fire authorities said. More news about our planet: Sign up for USA TODAY's Climate Point newsletter. Trump pardons Florida divers who freed sharks Presidential pardons have often sparked controversy, but Donald Trump's latest gesture had some teeth to it. Trump granted full clemency to two Florida divers, John Moore Jr. and Tanner Mansell, who were convicted of theft for cutting 19 sharks free from a fisherman's longline in 2020. They had assumed the gear was illegal; it turns out it belonged to a vessel permitted by the federal government to harvest sandbar sharks for research. "Whether people believe in his politics or not, he chose to pardon me ... and only ever wanted to help," Mansell said in a text. "I can't help but feel extremely grateful." A fortune sits in 'lost' 401(k) accounts You might think it would be hard to forget almost $60,000. But at least $1.7 trillion is wasting away in forgotten 401(k) accounts, the financial firm Capitalize found, and the average lost balance is $56,616. How does that happen? People who leave a job "usually have a bunch of things going on,' said David John of the AARP Public Policy Institute, and simply lose track. (More than 47 million Americans quit their jobs in the Great Resignation of 2021.) And someone who leaves a job after only a year or two might be especially prone to overlook a modest balance − which, thanks to the magic of tax-free investment growth, eventually turns into a big balance. Loretta Swit, 'M*A*S*H's beloved 'Hot Lips,' dies Fans, friends and co-stars were remembering Loretta Swit, who starred as Major Margaret "Hot Lips" Houlihan through all 11 seasons of TV's hugely popular Korean War dramedy "M*A*S*H" and gave depth and strength to a character who began as an oversexed blond stereotype. Swit, 87, died May 30. "More than acting her part, she created it," star Alan Alda, 89, posted on X. Jamie Farr, 90, who played Corporal Maxwell Q. Klinger, told USA TODAY she was his "adopted sister … as close as family can get." The cast was a tight-knit group through the years, Swit once said: "We might as well be joined at the hip." Close isn't good enough for the New York Knicks Some teams just want to win NOW. Maybe that's why the New York Knicks fired coach Tom Thibodeau, stunning much of the basketball world, just days after the franchise flirted with the NBA Finals for the first time in 25 years before falling to the Indiana Pacers. Not bad for a team that had won just 21 games in the 2019-20 season before Thibodeau took over. The Knicks might be forgiven for being a little impatient after their magical run, however: They have not won a title since 1973. (The NBA Finals, with the Pacers facing the Oklahoma City Thunder, tipped off June 5). − Compiled by Robert Abitbol, USA TODAY copy chief
Yahoo
11 hours ago
- Yahoo
Earn up to 110,000 bonus miles with a new Delta SkyMiles credit card
American Express and Delta are out with all-new welcome bonus offers across three personal credit cards within the Delta SkyMiles suite: Delta SkyMiles® Gold American Express Card: Earn 80,000 bonus miles after spending $3,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Platinum American Express Card: Earn 90,000 bonus miles after spending $4,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Reserve American Express Card: Earn 100,000 bonus miles after spending $6,000 on eligible purchases in your first six months of card membership. There are also new offers on Delta business cards: Delta SkyMiles® Gold Business American Express Card: Earn 90,000 bonus miles after spending $6,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Platinum Business American Express Card: Earn 100,000 bonus miles after spending $8,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Reserve Business American Express Card: Earn 110,000 bonus miles after spending $12,000 on eligible purchases in your first six months of card membership. With over 290 destinations across six continents and more than 200 million customers served in 2024, Delta is one of the most well-known airlines worldwide. And you could reduce much of the upfront cost of flying to one of Delta's global destinations if you're able to take advantage of these generous sign-up bonuses. It depends on how you redeem the miles, but we value Delta SkyMiles at an average of 1.18 cents each. That means 100,000 miles equals about $1,180. However, as with many airline credit cards, the exact value of your miles depends on how you use them. Since Delta uses dynamic pricing, you can see different values with each redemption. You can find plenty of value with 100,000 (give or take, depending on the welcome offer) Delta SkyMiles. This is especially true when accounting for the TakeOff 15 benefit, which provides an automatic 15% discount on eligible award flights for Delta SkyMiles cardholders. Let's take a look at some possible redemptions. You can fly from Los Angeles (LAX) to Auckland (AKL) for 38,200 miles. The cash price for the same flight is $1,341, giving you a redemption value of about 3.5 cents per mile ($1,341 / 38,200 = 0.035104). You'll still have plenty of miles left to figure out your return flight, which could mean including a stop in Australia after visiting Hobbiton (and while you're in the area). This flight from Salt Lake City (SLC) to Mexico City (MEX) will only set you back 26,300 miles. The redemption value for this flight is about 1.5 cents per mile, which is better than our average valuation. And with miles to spare, you can bring some friends or work on covering the return leg home. You don't have to get fancy with your redemptions; a short flight will do just fine if it saves you money, especially if it's a route you frequently take. Consider this example: A flight between Atlanta (ATL) and Miami (MIA) that costs 8,300 miles or $117. With 100,000 miles, you could take this flight 12 times, giving you plenty of opportunities for vacations or visiting friends and family. This particular flight has a redemption value of about 1.4 cents per mile. See which flavor — Gold, Platinum, or Reserve — of Delta SkyMiles card is the best fit for you. Consider which Delta SkyMiles business card is right for you if you run a small best Delta SkyMiles credit card for you depends on your goals and spending habits. If you only fly occasionally, maybe a few times per year, we recommend the Delta SkyMiles Gold Amex Card. This card has the lowest annual fee but still provides one of the best benefits: a free checked bag. With only a few roundtrip flights, you can offset the annual fee in saved baggage charges. If you travel a lot, a card like the Delta SkyMiles Platinum Amex Card or Delta SkyMiles Reserve Amex Card may make more sense. These cards have higher annual fees, but they also provide more benefits. For example, the Delta Reserve Amex Card offers Delta Sky Club Access (at least 15 visits each Medallion year), which could come in handy the more you find yourself in airports. Business owners can apply for the personal or business versions of the Delta SkyMiles credit cards. The business credit cards are largely the same as their personal variants, but their welcome offers require increased spending, so keep that in mind when making your decision. All the Delta SkyMiles credit cards associated with these new welcome offers have annual fees. If you want to avoid an annual fee at all costs, consider no-annual-fee credit Disclosure: The information in this article has not been reviewed or approved by any advertiser. All opinions belong solely to the Yahoo Finance and are not those of any other entity. The details on financial products, including card rates and fees, are accurate as of the publish date. All products or services are presented without warranty. Check the bank's website for the most current information. This site doesn't include all currently available offers. Credit score alone does not guarantee or imply approval for any financial product.
